Apatinib With Postoperative Adjuvant Chemotherapy for Operable Colorectal Cancer

Trial Profile

Apatinib With Postoperative Adjuvant Chemotherapy for Operable Colorectal Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Rivoceranib (Primary) ; Capecitabine; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jan 2018 Planned End Date changed from 30 Apr 2023 to 1 Mar 2023.
    • 10 Jan 2018 Planned primary completion date changed from 30 Apr 2022 to 1 Mar 2021.
    • 27 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top